CENIX BIOSCIENCE Announces Collaboration with Bayer HealthCare AG to Discover and Validate Novel Therapeutic Targets
"Having launched these HT-RNAi research offerings only this summer after years of careful R&D, we have been particularly gratified by the overwhelming market interest, of which this agreement represents a first, important milestone" said Dr Echeverri, CEO and CSO of Cenix BioScience GmbH.
The project will make use of the genome-wide library of siRNA molecules designed by Cenix using its industry-leading algorithms and produced by Ambion, Inc. (Austin, TX, USA). Under the deal, Cenix will receive upfront payments and research funding, and is eligible for downstream milestone payments. Bayer will have the option to obtain all rights to new intellectual property generated by the project.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic World Cell Analysis
Cell analyse advanced method allows us to explore and understand cells in their many facets. From single cell analysis to flow cytometry and imaging technology, cell analysis provides us with valuable insights into the structure, function and interaction of cells. Whether in medicine, biological research or pharmacology, cell analysis is revolutionizing our understanding of disease, development and treatment options.
Topic World Cell Analysis
Cell analyse advanced method allows us to explore and understand cells in their many facets. From single cell analysis to flow cytometry and imaging technology, cell analysis provides us with valuable insights into the structure, function and interaction of cells. Whether in medicine, biological research or pharmacology, cell analysis is revolutionizing our understanding of disease, development and treatment options.